Celgene Teams Up With Agios In Long-Term Cancer Metabolism Pact

The April 15 deal between Agios Pharmaceuticals Inc., a start-up barely two years old working in a novel area of cancer research, and Celgene Corp. is noteworthy for a number of reasons, among them its sheer size: the $130 million up-front payment associated with the deal is the largest year-to-date for a pharmaceutical alliance for which metrics have been disclosed, and is particularly hefty for a start-up that has yet to put a molecule in the clinic.

The April 15 deal between Agios Pharmaceuticals Inc., a start-up barely two years old working in a novel area of cancer research, and Celgene Corp. is noteworthy for a number of reasons. [See Deal] The $130 million up-front payment associated with the deal is the largest year-to-date for a pharmaceutical alliance for which metrics have been disclosed, and is particularly hefty for a start-up that has yet to put a molecule in the clinic. The alliance also demonstrates how smaller biotechs are increasingly looking to big-sibling relationships with larger pharmaceutical companies to drive long term sustainability. Indeed, the agreement is reminiscent of Regeneron Pharmaceuticals Inc.'s partnership with Sanofi in the antibody discovery space or Purdue Pharma LP/Mundipharma International Corp. Ltd.'s alliance with oncology player Infinity Pharmaceuticals Inc.[See Deal][See Deal] ( See "Sanofi Makes its Biggest External Play Yet With Long-Term Regeneron Deal," IN VIVO , December 2009 Also see "Sanofi Makes its Biggest External Play Yet With Long-Term Regeneron Deal" - In Vivo, 1 December, 2009. and "Infinity/Purdue: The Challenge of Reprising Roche/Genentech," IN VIVO , January 2009 Also see "Infinity/Purdue: The Challenge of Reprising Roche/Genentech" - In Vivo, 1 January, 2009..) Given Agios' status as a private company, it's also surprising that the start-up's backers would consider tying the high flying biotech so closely to one potential acquirer so early in its life cycle.

In exchange for a significant up-front cash payment, which includes what Agios management describes as a "modest" undisclosed equity investment,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

Final Chance To Have Your Say: Take Scrip's Reader Survey This Week

 

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access Scrip, or if you love it how it is, now is the time to have your voice heard.

Galapagos Expands Point-Of-Care CAR-T Study To The US

 

CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.

Analysts Split On Eisai’s Chances Of Changing EU Regulator’s Mind On Leqembi

 

A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand

More from Scrip

Stock Watch: When The Biotech Bandwagon Music Stops

 
• By 

The number of viable biotech companies exploiting a particular technology should be limited by intellectual property but the number of biotech IPOs exploiting that same technology always seems greater than those with freedom to operate.

Lilly’s Muscle Builder Looks Strong In GLP-1 Obesity Combo

 

Bimagrumab added to Wegovy increased weight loss and preserved muscle mass, but analysts want to see more safety and efficacy results from a combination with Zepbound.

Mineralys Eyes NDA As Lorundrostat Scores CKD Win In Race With AstraZeneca

 

As it races AstraZeneca’s baxdrostat to market, Mineralys plans to file an NDA later this year, backed by strong efficacy and safety data across four trials.